In the dose expansion phase, of the 18 patients enrolled for evaluable response, 5 had cholangiocarcinoma, of which 4 harbored FGFR2-fusion and one with FGFR1-fusion, being the only one who had PD after treatment. This evidence concerns the gene FGFR2 and cholangiocarcinoma.